WallStSmart

BioNexus Gene Lab Corp Common stock (BGLC)vsSouthern Copper Corporation (SCCO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Southern Copper Corporation generates 273866% more annual revenue ($14.55B vs $5.31M). SCCO leads profitability with a 34.1% profit margin vs -54.7%. SCCO earns a higher WallStSmart Score of 65/100 (B-).

BGLC

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 7.52

SCCO

Strong Buy

65

out of 100

Grade: B-

Growth: 9.3Profit: 10.0Value: 3.7Quality: 8.0
Piotroski: 5/9Altman Z: 3.11

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGLC3 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.5210/10

Safe zone — low bankruptcy risk

SCCO6 strengths · Avg: 10.0/10
Return on EquityProfitability
44.9%10/10

Every $100 of equity generates 45 in profit

Profit MarginProfitability
34.1%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
58.3%10/10

Strong operational efficiency at 58.3%

Revenue GrowthGrowth
36.2%10/10

Revenue surging 36.2% year-over-year

EPS GrowthGrowth
66.7%10/10

Earnings expanding 66.7% YoY

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

Areas to Watch

BGLC4 concerns · Avg: 2.5/10
Market CapQuality
$3.72M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-35.9%2/10

ROE of -35.9% — below average capital efficiency

Revenue GrowthGrowth
-98.9%2/10

Revenue declined 98.9%

SCCO3 concerns · Avg: 3.3/10
P/E RatioValuation
31.8x4/10

Premium valuation, high expectations priced in

Price/BookValuation
13.1x4/10

Trading at 13.1x book value

PEG RatioValuation
5.412/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BGLC

The strongest argument for BGLC centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : SCCO

The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 34.1% and operating margin at 58.3%. Revenue growth of 36.2% demonstrates continued momentum.

Bear Case : BGLC

The primary concerns for BGLC are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : SCCO

The primary concerns for SCCO are P/E Ratio, Price/Book, PEG Ratio.

Key Dynamics to Monitor

BGLC profiles as a turnaround stock while SCCO is a growth play — different risk/reward profiles.

BGLC carries more volatility with a beta of 2.21 — expect wider price swings.

SCCO is growing revenue faster at 36.2% — sustainability is the question.

SCCO generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

SCCO scores higher overall (65/100 vs 29/100), backed by strong 34.1% margins and 36.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioNexus Gene Lab Corp Common stock

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.

Southern Copper Corporation

BASIC MATERIALS · COPPER · USA

Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.

Visit Website →

Want to dig deeper into these stocks?